Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).

De Padua Silva Leandro, Rima Saliba, Donna McCormick, Grace-Julia Okoroji, Amin Alousi, Paolo Anderlini, Stefan Ciurea, Chitra Hosing, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Naoto Ueno, John McMannis, Richard Champlin, Barbara Pro, Issa F Khouri

Blood (2009) 114 (22): 3213.

https://doi.org/10.1182/blood.V114.22.3213.3213

Published: 2009

Journal Articles

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Blood (2009) 114 (22): 868.

https://doi.org/10.1182/blood.V114.22.868.868

Published: 2009

Journal Articles

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Blood (2007) 110 (11): 1984.

https://doi.org/10.1182/blood.V110.11.1984.1984

Published: 2007

Journal Articles

Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin’s Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.

Paolo Anderlini, M.D., Sandra A. Acholonu, Grace-Julia Okoroji, Rima Saliba, Sergio A. Giralt, Naoto Ueno, Michele L. Donato, Borje S. Andersson, Richard E. Champlin

Blood (2004) 104 (11): 1654.

https://doi.org/10.1182/blood.V104.11.1654.1654

Published: 2004

Journal Articles

Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.

Richard Champlin, M.D., Daniel Booser, M.D., Gabriela Rondon, M.D., Patricia Williams, R.N., Richard Wendt, Ph.D., Gabriel Hortobagyi, M.D., Naoto Ueno, M.D., Donald Podoloff, M.D.

Blood (2004) 104 (11): 5239.

https://doi.org/10.1182/blood.V104.11.5239.5239

Published: 2004

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.

Marcos de Lima, Munir Shahjahan, Jorge Alamo, Patricia Williams, Brigitte von Wolff, Daniel Couriel, Issa Khouri, Gabriela Rondon, Brandy Wheeler, Elihu Estey, Naoto Ueno, Partow Kebriaei, Richard Champlin, Sergio Giralt

Blood (2004) 104 (11): 2301.

https://doi.org/10.1182/blood.V104.11.2301.2301

Published: 2004

Journal Articles

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Marcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, Munir Shahjahan, Naoto Ueno, Cindy Ippoliti, Borje S. Andersson, James Gajewski, Daniel Couriel, Jorge Cortes, Michele Donato, Joyce Neumann, Richard Champlin, Sergio Giralt

Blood (2004) 104 (3): 865–872.

https://doi.org/10.1182/blood-2003-11-3750

Published: 2004

NARROW

Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin’s Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.

Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin’s Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.

Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only